Major Depressive Disorder Market Trends, Top Companies, Share, Growth And Forecast 2033

The new report published by The Business Research Company, titled Major Depressive Disorder Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the major depressive disorder market size has grown steadily in recent years. It will grow from $5.96 billion in 2023 to $6.12 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The major depressive disorder market size is expected to see steady growth in the next few years. It will grow to $6.84 billion in 2028 at a compound annual growth rate (CAGR) of 2.8%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

Surge In Substance And Alcohol Abuse Cases Amplifies Growth In Major Depressive Disorder Market
The rise in cases of substance abuse and alcohol abuse is expected to propel the growth of the major depressive disorder market. Substance and alcohol abuse are terms used to describe patterns of excessive and harmful use of substances, including alcohol, that can lead to negative physical, psychological and social consequences. It commonly co-occurs with major depressive disorder and both conditions tend to feed off each other and significantly increase the risk of physical and mental harm. For instance, in December 2022, according to reports shared by the Office for National Statistics (ONS), a UK-based government department, in 2022, 862,000, or 2.6%, of adults between the ages of 16 and 59 reported using drugs, compared to 2.1% in 2020. Furthermore, in December 2022, according to a report published by Kirin Holdings Company Limited, a Japan-based beverage company, around 185.60 million kiloliters of beer were consumed globally in 2021, an increase of 4.0% from the year before. Therefore, the rise in cases of substance abuse and alcohol abuse is driving the growth of the major depressive disorder market.

Innovative Approaches And Approvals Reshaping Major Depressive Disorder Treatment Market
Major companies operating in the major depressive disorder market focus on developing innovative products and getting them approved to gain a competitive advantage. Drug approvals for major depressive disorder treatment, such as VRAYLAR (cariprazine), are increasing due to the need for more effective and safer treatments. For instance, in December 2022, AbbVie Inc., a US-based pharmaceutical company, received approval for VRAYLAR (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults from the Food and Drug Administration (FDA), a US-based federal agency. VRAYLAR is an innovative atypical antipsychotic medication that balances dopamine and serotonin levels in the brain. It is the first atypical antipsychotic to be approved as an adjunctive treatment for major depressive disorder. Additionally, it is available in capsule form and is taken once daily.

The major depressive disorder market covered in this report is segmented -

1) By Treatment: Psychotherapy; Medications; Electroconvulsive Therapy (ECT); Transcranial Magnetic Stimulation (TMS); Other Treatments
2) By Diagnosis: Physical Examinations; Laboratory Tests; Psychiatric Evaluations; Diagnostic And Statistical Manual of Mental Disorders (DSM-5); Other Diagnosis
3) By End-User: Clinics; Hospitals; Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13042&type=discount

Major players in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Contents of the report:
1. Executive Summary
2. Major Depressive Disorder Market Report Structure
3. Major Depressive Disorder Market Trends And Strategies
4. Major Depressive Disorder Market - Macro Economic Scenario
5. Major Depressive Disorder Market Size And Growth
…..
27. Major Depressive Disorder Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.